Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.

Therapeutic drug monitoring - 1 Jun 2004

Penzak Scott R, Shen Jean M, Alfaro Raul M, Remaley Alan T, Natarajan Ven, Falloon Judith

Abstract excerpt

Our objective was to examine the influence of ritonavir on P-glycoprotein (P-gp) activity in humans by characterizing the effect of ritonavir on the pharmacokinetics of the P-gp substrate digoxin in individuals with known MDR1 genotypes. Healthy volunteers received a single dose of digoxin 0.4 mg orally before and after 14 days of ritonavir 200 mg twice daily. After each digoxin dose blood and urine were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Digoxin
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, MDR

Share to HIV Protease Inhibitors

Share to Metabolic Clearance Rate

Share to Patient Compliance

Share to Ritonavir

Source

Identifiers

PMID: 15167636
DOI: 10.1097/00007691-200406000-00018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.PMID 15167636Read ↗

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.Semantic proximity Read ↗

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.Semantic proximity Read ↗

Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.Semantic proximity Read ↗

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.Semantic proximity Read ↗

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.Semantic proximity Read ↗

Digoxin pharmacokinetics and MDR1 genetic polymorphisms.Semantic proximity Read ↗

Human intestinal P‐glycoprotein activity estimated by the model substrate digoxinSemantic proximity Read ↗

Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activitySemantic proximity Read ↗

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.Semantic proximity Read ↗

Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Semantic proximity Read ↗

Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers.Semantic proximity Read ↗

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.